Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

ClinicalTrials.gov ID

NCT06568549

Lead Sponsor

Mayo ClinicOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

350Estimated

Last Update Posted

Mar 20, 2026Actual

Start Date

Jun 13, 2025Actual

Primary Completion Date

Dec 31, 2030Estimated

Completion Date

Mar 31, 2031Estimated

Official Title

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf® Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Brief Summary

The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.

Detailed Description

Participation will be two years and it involves blood collection, collection of medical information and images from standard of care kidney biopsies. Subjects will be asked to complete questionnaires for the study at 12 and 24 months after kidney transplant. The research blood tests that are being collected for the study are called Trugraf®, Eurofins TRAC®, Trac-ID and Immunophenotyping and Single Cell RNA -sequencing. The principal investigator is using this test to see if they can predict and monitor rejection and viral infections in our kidney transplant patients. Immunophenotyping and single cell RNA sequencing tests are being done to identify unique gene expression profiles and their functions in different immune cells.

At the time of the 4 month standard of care follow up visit, if participants have not experienced any rejection episodes or formed any donor specific antibodies (dnDSA) and are still eligible, randomization will occur. Participants will be put into 1 of 2 groups: Mycophenolate Mofetil Maintenance group where the subject would continue on current medication, or the subject will be placed into the MMF Withdrawal group which means they would slowly be withdrawn from this medication. If the subject is not eligible to be randomized, they will remain in the study and placed into the Non-Randomized group and continue to have study related visits and procedures like the MMF Maintenance group.

• Kidney Transplantation
• Mycophenolate Mofetil

• Mycophenolate Mofetil (MMF) Maintenance Group
• Mycophenolate Mofetil (MMF) Withdrawal Group

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Solitary kidney transplant recipient >55 years of age. At most 1 prior solitary kidney transplant.
• No other solid organ transplant though recipients of autologous stem cell transplants are eligible.
• HIV negative.
• Subjects must be on tacrolimus and mycophenolate mofetil or Myfortic at the time of consent. Prednisone at the time of consent is optional and is per local standard of care. Patients randomized to MMF withdrawal will be placed on prednisone 5mg/d at 4 months. Use of other immunosuppression medications for maintenance (cyclosporine, azathioprine, belatacept, sirolimus) is excluded.

Exclusion Criteria:

Time of Transplant Exclusion Criteria:

• The results of the most recent DSA testing indicate DSA with an MFI >2000.

• The results of the most recent cPRA testing indicate cPRA is above >80% (based on MFI >2000).

  4-Month Exclusion Criteria:

• Acute rejection episode either clinical or on biopsy (greater than borderline). Subjects must not experience any type of rejection episodes from the time of transplant and must not show any signs of rejection (Cellular or Antibody mediated rejection, excluding borderline) at their 4-month biopsy (If obtained per standard of care). Subjects experiencing rejection will not be eligible for randomization and MMF withdrawal.

• De novo DSA

• Subjects who are not on tacrolimus at the time of randomization will be placed in the non-randomized group.

• Subjects who at the time of or prior to randomization were maintained on mycophenolate mofetil or Myfortic and have had their medication held or temporarily discontinued due to clinical indications (toxicity to the medication, polyoma virus infections, cancer, etc.) remain eligible for randomization.

• Has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings which, in the opinion of the investigator, would make study participation not in the participants best interest (e.g., compromise the well-being) or that could prevent, or limit the protocol-specified assessment.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Mayo ClinicOTHER

Collaborators

Transplant Genomics, Inc.INDUSTRY

EurofinsINDUSTRY

legaspi.david@mayo.edu904-953-4990

braaten.nong@mayo.edu507-266-6893

• Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients

  NCT07806136

  Not yet recruitingInterventionalEarly Phase 1Updated Sep 8, 2026
• Minimizing Immunosuppression in Old for Old Kidney Transplantation

  NCT00912678

  CompletedInterventionalPhase 4Updated Jun 3, 2009
• Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation

  NCT00693381

  CompletedInterventionalPhase 3Updated Sep 18, 2014
• RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

  NCT03797196

  Active, not recruitingInterventionalPhase 4Updated May 10, 2023
• REgulatory T Cell Therapy to Achieve Immunosuppression REduction

  NCT06552169

  RecruitingInterventionalPhase 2Updated Apr 27, 2026
• Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients

  NCT01213394

  TerminatedInterventionalPhase 3Updated Apr 19, 2012